#Italy #Florence #Menarini Group #Global Health #Thomas Cueni

Menarini Group Strengthens Leadership with New Board Member

The Menarini Group, a prominent multinational pharmaceutical company based in Florence, has named Thomas Cueni as its newest Board member, aiming to enhance the leadership structure within the organization. With a robust career spanning nearly four decades in the pharmaceutical sector, Cueni's extensive experience is expected to lead the group into new heights of excellence and innovation in healthcare.

Experience in Global Health

Cueni brings with him a wealth of international experience, having held significant positions including Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and a board member at the European Federation of Pharmaceutical Industries and Associations (EFPIA). Throughout his career, he has been instrumental in advocating for improved access to treatments for chronic diseases and has shaped policies that address global health challenges, including the COVID-19 pandemic.

One of Cueni's notable accomplishments is his foundational role in creating the AMR Action Fund, a multi-billion dollar initiative dedicated to supporting the development of new antibiotics. Furthermore, he has also served as the founding president of the AMR Industry Alliance, one of the largest private sector coalitions working on sustainable solutions to combat antibiotic resistance.

Commitment to Patient Improvement

In a statement regarding his appointment, Cueni expressed his pride in contributing his experience and dedication to Menarini, highlighting the company's commitment to scientific excellence and innovation. He stated, "Joining a dynamic and growing company that embodies a commitment to global health is a unique opportunity for me to positively impact the lives of patients, wherever they may be."

The Aleotti family, key shareholders of Menarini, along with the Board members, also welcomed Cueni, emphasizing that his vast experience aligns closely with Menarini's mission to innovate and improve patient care. They noted that Cueni's appointment not only strengthens their leadership but also marks a significant step toward tackling the fast-evolving challenges facing the pharmaceutical industry in an increasingly complex global geopolitical environment.

Continued Global Presence

Founded in Florence, the Menarini Group has a consolidated revenue of €4.88 billion and employs over 17,000 professionals across 140 countries worldwide. Menarini's portfolio includes products in vital therapeutic areas such as cardiometabolic diseases, oncology, gastroenterology, pulmonology, and anti-inflammatory/analgesic medications. The company's commitment to research and development, along with high-quality production standards, underlines its ongoing role in enhancing patient health globally.

In closing, Cueni’s addition to the Board represents more than just a strengthening of Menarini's leadership; it signifies a proactive approach to navigating the complexities of the pharmaceutical landscape while staying committed to patient care and innovative solutions.